Image Presentation
Von Hippel Lindau Syndrome with Renal Cell Carcinoma, Pancreas Serous Cystadenoma, Hemangioblastoma and NET Demonstrated on Ga-68 DOTATATE PET-CT and FDG PET-CT Imaging
Abstract
Von Hippel–Lindau disease (VHL), also known as Von Hippel–Lindau syndrome, is a rare genetic disorder with multisystem involvement (1). Imaging plays an important role in the evaluation of cancer patients. In recent years, much attention has been focused on 68Ga-PSMA PET-CT. We hereby, report the rare case of a Von Hippel Lindau Syndrome with renal cell carcinoma, pancreas cystadenoma, hemangioblastoma and pancreatic NET demonstrated on both Ga-68 PSMA and FDG PET-CT imaging.
References
- 1. Von Hippel-Lindau disease, Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 2018-04-17
- 2. Lindsay, Kenneth W; Ian Bone; Robin Callander; J. van Gijn (1991). Neurology and Neurosurgery Illustrated. United States: Churchill Livingstone. ISBN 978-0-443-04345-1
- 3. Frantzen, Carlijn; Links, Thera P.; Giles, Rachel H. (21 June 2012). "Von Hippel-Lindau Syndrome". Von Hippel-Lindau Disease. GeneReviews at NCBI. University of Washington, Seattle. Retrieved 30 March 2013
- 4. Maher ER; Glenn GM; Walther M; et al. (June 2011). "von Hippel-Lindau disease: a clinical and scientific review". European Journal of Human Genetics. 19 (6): 617–23
- 5. Friedrich, CA (December 1, 1999). "Von Hippel-Lindau syndrome. A pleomorphic condition". Cancer. 86 (11 Suppl): 2478–82
- 6. Leung RS, Biswas SV, Duncan M, et al. Imaging features of von Hippel-Lindau disease. Radiographics. 2008; 28:65–67
- 7. Ambrosini V, Campana D, Allegri V, et al. 68Ga-DOTANOC PET/CT detects somatostatin receptors expression in von Hippel-Lindau cerebellar disease. Clin. Nucl. Med. 2011; 36:64–65.
- 8. Oh JR, Kulkarni H, Carreras C, et al. Ga-68 Somatostatin Receptor PET/CT in von Hippel-Lindau Disease. Nucl. Med. Mol. Imaging. 2012; 46:129–133
- 9. Papadakis G.Z., Millo C, Sadowski SM, et. al. Epididymal cystadenomas in von Hippel-Lindau disease showing increased activity on 68Ga-DOTA-TATE PET/CT. Clin Nucl Med. 2016 October ; 41(10): 781–782
- 10. Sizdahkhani S, Michael J. Feldman MJ.,Martin G. Piazza MG., et. al. Somatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target. Scientific Reports | 7:40822 | DOI: 10.1038/srep40822
- 11. Papadakis G.Z., Millo C, Sadowski SM, et. al. Endolymphatic sac tumor showing increased activity on 68 Ga-DOTA-TATE PET/CT. Clin Nucl Med. 2016 October; 41(10): 783–784
- 12. Leung RS, Biswas SV, Duncan M, et al. Imaging features of von Hippel-Lindau disease. Radiographics. 2008; 28:65–67
- 13. Wood CG, Stromberg LJ, Harmath CB, et al. CT and MR imaging for evaluation of cystic renal lesions and diseases. Radiographics. 2015; 35:125–141.
- 14. Hofman MS, Lau WF, Hicks RJ. Somatostatin Receptor Imaging with 68Ga-DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015; 35:500–516
- 15. Papadakis GZ, Bagci U, Sadowski SM, et al. Ectopic ACTH and CRH co-secreting tumor localized by 68Ga-DOTA-TATE PET/CT. Clin Nucl Med. 2015; 40:576–578
- 16. Papadakis G.Z., Millo C, Sadowski SM, et. al. Kidney tumor in a von Hippel-Lindau (VHL) patient with intensely increased activity on 68 Ga-DOTA-TATE PET/CT. Clin Nucl Med. 2016 December; 41(12): 970–971
There are 16 citations in total.
Details
| Primary Language | English |
|---|---|
| Subjects | Oncology and Carcinogenesis |
| Journal Section | Image Presentation |
| Authors | |
| Publication Date | April 15, 2022 |
| IZ | https://izlik.org/JA23HJ32SX |
| Published in Issue | Year 2022 Volume: 2 Issue: 1 |